Navigation Links
Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
Date:2/12/2008

red with non-GAAP net income of $7.7 million, or $0.63 per diluted share, in 2006. Please refer to the financial reconciliations included in this news release for a reconciliation of GAAP results to non-GAAP results for the year ended December 31, 2007 and 2006.

Cash, cash equivalents and marketable securities at December 31, 2007 were $86.1 million, compared with $57.2 million as of December 31, 2006.

Business Outlook

"A combination of product innovation and sales force excellence enabled us to deliver an outstanding year in 2007, and we expect that momentum to continue in 2008," Davin said. "Bolstered by Affirm and Smartlipo, our recent product introductions at AAD and new innovations planned for the coming quarters, we believe we are well positioned to produce sustained, profitable growth. Our goal is to continue to grow faster than the aesthetic market in the year ahead."

Use of Non-GAAP Financial Measures

To supplement Cynosure's consolidated financial statements presented in accordance with GAAP, this press release includes the following measures defined as non-GAAP financial measures by the SEC: non-GAAP net income and non-GAAP diluted earnings per share. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. In addition, the non-GAAP financial measures included in this press release may be different from, and therefore not comparable to, similar measures used by other companies. Although certain non-GAAP financial measures used in this release exclude the accounting treatment of stock-based compensation, these non-GAAP measures should not be relied upon independently, as they ignore the contribution to our operating results that is generated by the incentive and compensation effects of the underlying stock-based compensation programs. For more information on these non-GAAP financial measures
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
2. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
3. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
4. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
5. Immtech Reports Fiscal Third Quarter 2008 Results
6. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
7. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
8. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
9. Bunge Reports Fourth Quarter Net Income of $245 Million
10. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
11. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... UPTON, NYElectronic devices with unprecedented efficiency and ... materials that use built-in electric polarizations to ... magnets inside most popular data-driven technology. But ... stumbling blocks, including a curious habit of ... at the U.S. Department of Energy,s Brookhaven ...
(Date:8/18/2014)... According to a new ... Science Reagents Market(Products- PCR Reagent Kits, Cell and ... Reagents and Others; End Users- Commercial and Contract ... Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, ... life science reagents market was valued at USD ...
(Date:8/18/2014)... Aug. 18, 2014 TNI BioTech, Inc. (OTC-BB: ... the manufacturing and marketing of innovative therapies for autoimmune ... is providing a second notice of TNI BioTech,s annual ... the announcement, Noreen Griffin , founder and CEO ... for your participation in the Annual Meeting. On behalf ...
(Date:8/18/2014)... August 18, 2014 China is ... for the clinical research industry. Clinicaltrial.gov statistics highlight ... to its aging population; a high increase in ... a densely populated pool of patients and a ... these positive points, China also presents challenges for ...
Breaking Biology Technology:Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
... and NEW YORK, Sept. 17 ,Microbia, Inc. ... ), today announced,that they have entered into ... to,co-develop and co-market Microbia,s first-in-class compound linaclotide.,Linaclotide ... of,constipation-predominant irritable bowel syndrome (IBS-C), chronic,constipation (CC), ...
... Experience in Pulmonary and Infectious Disease ... ... a,clinical stage biopharmaceutical company focused on developing products to,overcome issues of ... Company,s Chief Medical Officer. Dr. Loutit,joins Mpex from InterMune, Inc. where ...
... Sept. 17 Kyphon Inc.,(Nasdaq: KYPH ... clearance from the,Federal Trade Commission (FTC) and ... Improvements Act of 1976 (as amended) with,respect ... assets,and associated intellectual property rights of Disc-O-Tech ...
Cached Biology Technology:Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 2Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 3Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 4Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 5Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 2Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 3Federal Trade Commission Clears Kyphon's Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech 2
(Date:8/19/2014)... parts of the world, leprosy and tuberculosis live ... of leprosy per year, with nearly all of ... available century-old vaccine Bacille Calmette-Guerin, or BCG, provides ... so a more potent vaccine is needed to ... a stronger weapon against both diseases., In a ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
(Date:8/19/2014)... been awarded a nearly $40,000 grant from the National ... of the National Park Service (NPS) and U.S. Department ... study of the energy efficiency and cost effectiveness of ... climates. , Radiant barriers are reflective thermal insulations commonly ... thereby reducing the amount of heat emitted in the ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Despite ongoing public health efforts, E. coli ... sickness and death throughout the world. But the ... published today in the scientific journal Nature , researchers ... discovered a molecule,s previously unknown role in fighting off ...
... of North Carolina scientists have uncovered a new strategy ... and chronic obstructive pulmonary disorder better clear the thick ... to life-threatening infections. In a new report appearing online ... researchers show that the "SPLUNC1" protein and its derivative ...
... July 13, 2012, Shenzhen, China - An international team, ... Academy of Science, and BGI, the world,s largest genomics ... salt cress ( Thellungiella salsuginea ), a wild salt-tolerant ... tool for exploring mechanisms of adaptive evolution and sheds ...
Cached Biology News:La Jolla institute identifies critical cell in fighting E. coli infection 2La Jolla institute identifies critical cell in fighting E. coli infection 3New proteins to clear the airways in cystic fibrosis and COPD 2Salt cress genome yields new clues to salt tolerance 2
Green Standard is fluorescein....
Red Standard is sodium salt of resorufin....
Human Jagged 2 Biotinylated Affinity Purified PAb...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: